Human NOV/CCN3 Antibody

Name: Human NOV/CCN3 Antibody
Brand: R&D Systems
SKU: MAB1640
Rating: 3.8 (4 reviews)

Catalog #: MAB1640
2 Citations 4 Reviews Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB1640-SP
MAB1640-500
MAB1640-100

All NOV/CCN3 Antibodies

Product Details

Citations (2)

FAQs

Supplemental Products

Reviews (4)

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human NOV/CCN3 Antibody Summary

Species Reactivity

Human

Specificity

Detects human NOV/CCN3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross-react with recombinant mouse NOV, recombinant human (rh) CTGF, or rhWISP-1.

Source

Monoclonal Mouse IgG₁ Clone # 209808

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human NOV/CCN3
Thr32-Met357
Accession # P48745

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Purity

Protein A or G purified from hybridoma culture supernatant

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human NOV/CCN3 (Catalog # 1640-NV)
under non-reducing conditions only

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: NOV/CCN3

NOV, also called CCN3, is one of six CCN (CYR61/CTGF/NOV) secreted proteins which share a common multimodular organization (1 - 4). NOV/CCN3 contains an N-terminal IGFBP domain that appears to be non-functional and a vWF type C and thrombospondin type I domain which mediate oligomerization and matrix interactions, respectively (1, 2). The C-terminal cysteine knot domain interacts with several partners, including the matrix protein fibulin 1C (5), Notch-1 (6), and CCN2, with which it may heterodimerize (2). NOV/CCN3 also interacts with the gap junction protein Connexin43 and mediates suppression of proliferation (7). It also binds the calcium binding protein S100A4 and promotes calcium channel activation (8). The 357 amino acid (aa), 44 kDa human NOV/CCN3 shares 80% aa identity with mouse, rat and dog NOV/CCN3, and 78% aa identity with cow NOV/CCN3. NOV/CCN3 also shows 38 - 50% aa identity with other family members including WISP proteins, except for WISP-2/CCN5 which lacks the cysteine knot (1). NOV/CCN3 is widely expressed developmentally, especially in muscle, endothelium, nervous system, adrenal cortex and chondrocytes (1 - 4). In transformed cells, a 32 kDa N-terminally truncated form lacks the signal sequence is localized to the nucleus. Truncation allows a C-terminal nuclear localization sequence to be active (9). Nuclear NOV/CCN3 acts as a transcriptional repressor but promotes proliferation, presumably by interfering with growth control (9). Full length NOV/CCN3 is a secreted matricellular protein which inhibits cell growth. Interaction of NOV/CCN3 with integrins alpha _v beta ₃ and alpha ₅ beta ₁ mediates endothelial cell adhesion, chemotaxis, and promotes angiogenesis (10, 11). Over-expression of NOV/CCN3 downregulates myogenic genes such as MyoD (12).

References

Perbal, B. (2004) Lancet 363:62.
Perbal, B. (2006) Cell Commun. Signal. 4:3.
Martinerie, C. et al. (1994) Oncogene 9:2729.
Snaith, M.R. et al. (1996) Genomics 38:425.
Perbal, B. et al. (1999) Proc. Natl. Acad. Sci. USA 96:869.
Sakamoto, K. et al. (2002) J. Biol. Chem. 277:29399.
Fu, C.T. et al. (2004) J. Biol. Chem. 279:36943.
Li, C.L. et al. (2002) Mol. Pathol. 55:250.
Planque, N. et al. (2006) J. Cell. Biochem. 99:105.
Lin, C.G. et al. (2003) J. Biol. Chem. 278:24200.
Lin, C.G. et al. (2003) J. Biol. Chem. 280:8229.
Calhabeu, F. et al. (2006) Exp. Cell. Res. 312:1876.

Long Name

Nephroblastoma Overexpressed Gene

Entrez Gene IDs

4856 (Human); 18133 (Mouse)

Alternate Names

CCN family member 3; CCN3; CCN3IGF-binding protein 9; IBP-9; IGFBP-9; IGFBP9novH; Insulin-like growth factor-binding protein 9; nephroblastoma overexpressed gene; Nephroblastoma-overexpressed gene protein homolog; NOV; NOVH; protein NOV homolog

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human NOV/CCN3 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

2 Citations: Showing 1 - 2
Filter your results:

Filter by:

Anti-CTGF single-chain variable fragment dimers inhibit human airway smooth muscle (ASM) cell proliferation by down-regulating p-Akt and p-mTOR levels.
Authors: Gao W, Cai L, Xu X, Fan J, Xue X, Yan X, Qu Q, Wang X, Zhang C, Wu G
PLoS ONE, 2014-12-05;9(12):e113980.
Species: Human
Sample Types: Recombinant Protein
Applications: ELISA Development
CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.
Authors: Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC
Am. J. Pathol., 2009-04-09;174(5):1725-34.
Species: Rat
Sample Types: Cell Culture Supernates, Cell Lysates
Applications: ELISA Development, Western Blot